FibroGen is a biopharmaceutical company that developes and commercializes a pipeline of therapeutics. Co. applies its capability in hypoxia-inducible factor (HIF) biology and connective tissue growth factor (CTGF) biology to develop medicines for the treatment of anemia, fibrotic disease, and cancer. Roxadustat, Co.'s main product, is an inhibitor of HIF-prolyl hydroxylase activity that acts by stimulating the body's natural pathway of erythropoiesis or red blood cell production. Pamrevlumab is Co.'s human monoclonal antibody that inhibits the activity of CTGF for the treatment of idiopathic pulmonary fibrosis, locally advanced unresectable pancreatic cancer, and Duchenne muscular dystroph. We show 39 historical shares outstanding datapoints in our FGEN shares outstanding history coverage, used to compute FGEN market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing FGEN market cap history over the course of time is important for investors
interested in comparing FGEN's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of FGEN versus a peer is one thing; comparing
FGEN market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like FGEN can fluctuate over the course of history.
With this page we aim to empower investors researching FGEN by allowing them to research the FGEN market cap history. |
Free FGEN Email Alerts:
Video: The Importance of Market Cap
